Richard bayney (30 resultados)

Hardcover. Condición: Acceptable. Connecting readers with great books since 1972. Used textbooks may not include companion materials such as access codes, etc. May have condition issues including wear and notes/highlighting. We ship orders daily and Customer Service is our top priority.

Hardcover. Condición: Very Good. No Jacket. Missing dust jacket; May have limited writing in cover pages. Pages are unmarked. ~ ThriftBooks: Read More, Spend Less.

Condición: acceptable. Used - Acceptable: All pages and the cover are intact, but shrink wrap, dust covers, or boxed set case may be missing. Pages may include limited notes, highlighting, or minor water damage but the text is readable. Item may be missing bundled media.

Paperback. Condición: Fine.

hardcover. Condición: Very Good. Most items will be dispatched the same or the next working day. A copy that has been read, but is in excellent condition. Pages are intact and not marred by notes or highlighting. The spine remains undamaged.

hardcover. Condición: Good. Ships in a BOX from Central Missouri! May not include working access code. Will not include dust jacket. Has used sticker(s) and some writing or highlighting. UPS shipping for most packages, (Priority Mail for AK/HI/APO/PO Boxes).

hardcover. Condición: New. BRAND NEW! Ships within 24 hours.

Condición: New.

Hardback. Condición: New. This unique guide and professional reference presents a structured framework for practitioners and students of project, program, and portfolio management to enhance their strategic and analytic capabilities in the evolving discipline of project portfolio management (PPM). It provides a practical, step-by-step approach to building competencies in categorizing, evaluating, optimizing, prioritizing, and managing an IT, pharmaceutical, biotech or other complex RandD-oriented portfolio of investments. …

Hardcover. Condición: Brand New. 376 pages. 10.00x1.10x7.10 inches. In Stock.

Condición: As New. Unread book in perfect condition.

HRD. Condición: New. New Book. Shipped from UK. Established seller since 2000.

Condición: New. pp. 356 Index.

Condición: New. pp. 356.

Hardcover. Condición: new. New Copy. Customer Service Guaranteed.

Condición: New. 2012. Hardcover. Offers a practical framework for implementing project portfolio management in R&D and IT enterprises. This title presents a structured framework for practitioners and students of project, program, and portfolio management to enhance their strategic and analytic capabilities in the evolving discipline of project portfolio management (PPM). Num Pages: 280 pages, black & white illustrations, black & white tables, figures. BIC Classification: KJMP. Category: (G) General (US: Trade). Dimension: 259 x 186 x 26. Weight in Grams: 836. . . . . .…

Condición: New.

Condición: New. 2012. Hardcover. Offers a practical framework for implementing project portfolio management in R&D and IT enterprises. This title presents a structured framework for practitioners and students of project, program, and portfolio management to enhance their strategic and analytic capabilities in the evolving discipline of project portfolio management (PPM). Num Pages: 280 pages, black & white illustrations, black & white tables, figures. BIC Classification: KJMP. Category: (G) General (US: Trade). Dimension: 259 x 186 x 26. Weight in Grams: 836. . . . . . Books ship from the US and Ireland.…

Condición: As New. Unread book in perfect condition.

Hardback. Condición: New. New copy - Usually dispatched within 4 working days.

Hardback. Condición: New. Biopharmaceutical RandD stands at a crossroads. Escalating development costs, persistent clinical attrition, heightened competitive pressures, mounting regulatory complexity, and uncertain commercial rewards have made ""doing more with less""; an inherently flawed strategy for success and sustainability. This one-of-a-kind book reframes the conversation, arguing that the true objective is not simply value creation, but value maximization under risk and uncertainty. By integrating decision analysis with enterprise portfolio management, it provides leaders with the intellectual and operational foundation required to make defensible, high-stakes investment decisions across drug discovery, clinical development, regulatory approval, and commercialization. Grounded in decades of real-world experience, the book builds on CREOPM, first introduced in 2012, as a pragmatic and maturity-sensitive framework designed to embed analytical rigor, strategic clarity, and disciplined governance into the fabric of RandD organizations. Moving beyond weak data gathering resulting in single-point estimates and deterministic scorecards, it demonstrates how probabilistic modeling, efficient-frontier thinking, and integrated evaluation can transform portfolio construction from reactive budgeting to systematic value optimization. The result is a comprehensive roadmap for organizations seeking sustained competitiveness, transparent decision lineage, and measurable performance improvement in complex Biopharma environments.…

Hardback. Condición: New. Biopharmaceutical RandD stands at a crossroads. Escalating development costs, persistent clinical attrition, heightened competitive pressures, mounting regulatory complexity, and uncertain commercial rewards have made ""doing more with less""; an inherently flawed strategy for success and sustainability. This one-of-a-kind book reframes the conversation, arguing that the true objective is not simply value creation, but value maximization under risk and uncertainty. By integrating decision analysis with enterprise portfolio management, it provides leaders with the intellectual and operational foundation required to make defensible, high-stakes investment decisions across drug discovery, clinical development, regulatory approval, and commercialization. Grounded in decades of real-world experience, the book builds on CREOPM, first introduced in 2012, as a pragmatic and maturity-sensitive framework designed to embed analytical rigor, strategic clarity, and disciplined governance into the fabric of RandD organizations. Moving beyond weak data gathering resulting in single-point estimates and deterministic scorecards, it demonstrates how probabilistic modeling, efficient-frontier thinking, and integrated evaluation can transform portfolio construction from reactive budgeting to systematic value optimization. The result is a comprehensive roadmap for organizations seeking sustained competitiveness, transparent decision lineage, and measurable performance improvement in complex Biopharma environments.…

Hardcover. Condición: Brand New. 340 pages. 7.00x0.90x10.00 inches. In Stock.

Condición: New. In English.

Hardback. Condición: New. This unique guide and professional reference presents a structured framework for practitioners and students of project, program, and portfolio management to enhance their strategic and analytic capabilities in the evolving discipline of project portfolio management (PPM). It provides a practical, step-by-step approach to building competencies in categorizing, evaluating, optimizing, prioritizing, and managing an IT, pharmaceutical, biotech or other complex RandD-oriented portfolio of investments. …

Hardback. Condición: New. Biopharmaceutical RandD stands at a crossroads. Escalating development costs, persistent clinical attrition, heightened competitive pressures, mounting regulatory complexity, and uncertain commercial rewards have made ""doing more with less""; an inherently flawed strategy for success and sustainability. This one-of-a-kind book reframes the conversation, arguing that the true objective is not simply value creation, but value maximization under risk and uncertainty. By integrating decision analysis with enterprise portfolio management, it provides leaders with the intellectual and operational foundation required to make defensible, high-stakes investment decisions across drug discovery, clinical development, regulatory approval, and commercialization. Grounded in decades of real-world experience, the book builds on CREOPM, first introduced in 2012, as a pragmatic and maturity-sensitive framework designed to embed analytical rigor, strategic clarity, and disciplined governance into the fabric of RandD organizations. Moving beyond weak data gathering resulting in single-point estimates and deterministic scorecards, it demonstrates how probabilistic modeling, efficient-frontier thinking, and integrated evaluation can transform portfolio construction from reactive budgeting to systematic value optimization. The result is a comprehensive roadmap for organizations seeking sustained competitiveness, transparent decision lineage, and measurable performance improvement in complex Biopharma environments.…

Condición: New.

Condición: New. 2026. hardcover. . . . . . Books ship from the US and Ireland.

Hardback. Condición: New. Biopharmaceutical RandD stands at a crossroads. Escalating development costs, persistent clinical attrition, heightened competitive pressures, mounting regulatory complexity, and uncertain commercial rewards have made ""doing more with less""; an inherently flawed strategy for success and sustainability. This one-of-a-kind book reframes the conversation, arguing that the true objective is not simply value creation, but value maximization under risk and uncertainty. By integrating decision analysis with enterprise portfolio management, it provides leaders with the intellectual and operational foundation required to make defensible, high-stakes investment decisions across drug discovery, clinical development, regulatory approval, and commercialization. Grounded in decades of real-world experience, the book builds on CREOPM, first introduced in 2012, as a pragmatic and maturity-sensitive framework designed to embed analytical rigor, strategic clarity, and disciplined governance into the fabric of RandD organizations. Moving beyond weak data gathering resulting in single-point estimates and deterministic scorecards, it demonstrates how probabilistic modeling, efficient-frontier thinking, and integrated evaluation can transform portfolio construction from reactive budgeting to systematic value optimization. The result is a comprehensive roadmap for organizations seeking sustained competitiveness, transparent decision lineage, and measurable performance improvement in complex Biopharma environments.…

Condición: New. 2026. hardcover. . . . . .